BARDA Official Worries About How Non-Traditional Antibiotics Will Get To Market
Executive Summary
Promising non-traditional antibiotic therapies need a clear path to market to entice investment, US Biomedical Advanced Research and Development Authority official says.
You may also be interested in...
Everything's Special At US FDA: Priority NDA/BLA Filings Surge
The FY 2018 PDUFA performance report also indicates that applications with standard assessments fell compared to long-term averages.
LPAD Approval Pathway Is Not Saving Antimicrobial Development
US FDA and CMS explore reimbursement ideas to strengthen business case for antimicrobial development; new approval pathway likely is only needed in special situations.
Non-Traditional Antimicrobials Can Follow Regulatory Path Laid By Small Molecule Antibiotics, US FDA Says
Live biotherapeutics, fecal microbiota transplants and bacteriophages may be novel when it comes to fighting hard-to-treat infections, but their development and route to approval may not be all that different than traditional antibiotics, officials from FDA’s drugs and biologics center say.